New hope for itchy blood cancer patients: drug showdown targets Water-Triggered agony

NCT ID NCT03808805

First seen Jan 10, 2026 · Last updated May 16, 2026 · Updated 18 times

Summary

This study tested two oral medications, aprepitant and hydroxyzine, to see which better reduces severe itching caused by water contact in people with certain blood cancers (myeloproliferative neoplasms). 63 participants received one of the drugs alongside their usual cancer treatment. The goal was to lower itching intensity to 3 or less on a 10-point scale.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELOPROLIFERATIVE DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • CHRU de Brest - Hôpital Morvan

    Brest, Brest Cedex, 29609, France

  • CHU Grenoble Alpes

    Grenoble, 38043, France

  • CHU d'Angers

    Angers, 49933, France

  • CHU de Caen

    Caen, 14033, France

  • CHU de Nantes

    Nantes, 44093, France

  • Centre Hospitalier de Cornouaille

    Quimper, Quimper, 29107, France

  • Centre Hospitalier de Douarnenez

    Douarnenez, 29171, France

  • Centre Hospitalier des Pays de Morlaix

    Morlaix, 29672, France

  • Centre Léon Bérard

    Lyon, 69373, France

  • Hôpital Pontchaillou

    Rennes, France

  • Hôpital Yves Le Foll

    Saint-Brieuc, 22027, France

Conditions

Explore the condition pages connected to this study.